Table 2.

Average (±SD) levels of haemoglobin, haematocrit, cholesterol, high‐density lipoprotein, low‐density lipoprotein, C‐reactive protein, and thyroid‐stimulating hormone in head and neck and cervical patients before and after receiving 7 weeks of treatment with testosterone or placebo

	Placebo			Testosterone
	Pre‐treatment	Post‐treatment	P	Pre‐treatment	Post‐treatment	P
Testosterone (ng/dL)a
Male	323.9 ± 191.3	318.4 ± 177.3	0.908	281.0 ± 156.5	889.7 ± 104.3	0.011
Female	25.4 ± 34.5	19.0 ± 14.5	0.573	16.8 ± 15.6	606.5 ± 184.3	<0.001
Free testosterone (pg/mL)a
Male	63.1 ± 41.8	48.7 ± 31.6	0.116	55.0 ± 30.8	133.0 ± 38.2	0.011
Female	3.7 ± 5.2	2.0 ± 1.6	0.397	1.9 ± 0.9	79.1 ± 43.0	0.019
SHBG (nmol/L)a
Male	42.3 ± 39.9	60.8 ± 53.1	0.032	29.7 ± 11.2	61.7 ± 24.7	0.103
Female	47.2 ± 12.7	80.3 ± 40.4	0.137	79.25 ± 34.0	73.25 ± 43.0	0.836
Hb (g/dL)
Male	10.8 ± 1.6	10.8 ± 1.0	0.962	11.6 ± 1.5	10.5 ± 0.7	INS
Female	9.4 ± 1.0	9.4 ± 1.0	0.951	10.4 ± 0.4	9.4 ± 0.7	0.066
HCT (%)
Male	33.2 ± 3.8	32.4 ± 1.7	0.741	35.1 ± 1.8	32.0 ± 2.3	INS
Female	29.3 ± 3.0	28.5 ± 2.8	0.350	31.1 ± 1.6	28.1 ± 1.5	0.209
Cholesterol (mg/dL)	139.9 ± 32.1	155.0 ± 28.6	0.092	175.0 ± 33.9	151.1 ± 46.4	0.179
HDL (mg/dL)	39.1 ± 16.5	43.2 ± 11.9	0.573	45.0 ± 13.0	41.2 ± 12.7	0.339
LDL (mg/dL)	76.0 ± 27.0	88.1 ± 20.7	0.010	106.9 ± 26.1	86.7 ± 37.0	0.133
C‐reactive protein (mg/dL)	7.2 ± 8.7	4.3 ± 5.4	0.623	6.7 ± 7.6	4.8 ± 7.9	0.973
TSH (μIU/mL)	2.1 ± 2.0	1.1 ± 1.1	0.143	2.1 ± 2.2	1.8 ± 2.1	0.135

^aPost‐treatment levels of testosterone, free testosterone, and sex hormone‐binding globulin (SHBG) are an average of mid and post‐treatment values.

INS means insufficient subgroup sample size for this measure.

Hb, haemoglobin; HCT, haematocrit; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; TSH, thyroid‐stimulating hormone.